Numerous case reports and case series have described new-onset central and peripheral nervous system demyelination, including MS, optic neuritis, transverse myelitis, Guillain-Barré syndrome, and CIDP, occurring in temporal association with all anti-TNF-α agents licensed for IBD.75–91. This evidence concerns the gene TNF and inflammatory bowel disease.